JP2025513930A5 - - Google Patents
Info
- Publication number
- JP2025513930A5 JP2025513930A5 JP2025503025A JP2025503025A JP2025513930A5 JP 2025513930 A5 JP2025513930 A5 JP 2025513930A5 JP 2025503025 A JP2025503025 A JP 2025503025A JP 2025503025 A JP2025503025 A JP 2025503025A JP 2025513930 A5 JP2025513930 A5 JP 2025513930A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- nanobody
- amino acid
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210345704.7A CN116925224A (zh) | 2022-04-02 | 2022-04-02 | 抗cd39纳米抗体及其应用 |
| CN202210345704.7 | 2022-04-02 | ||
| PCT/CN2023/085567 WO2023186121A1 (en) | 2022-04-02 | 2023-03-31 | Anti-cd39 nanobody and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513930A JP2025513930A (ja) | 2025-04-30 |
| JP2025513930A5 true JP2025513930A5 (https=) | 2026-04-08 |
Family
ID=88199508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025503025A Pending JP2025513930A (ja) | 2022-04-02 | 2023-03-31 | 抗ｃｄ３９ナノボディ及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250230255A1 (https=) |
| EP (1) | EP4504789A1 (https=) |
| JP (1) | JP2025513930A (https=) |
| KR (1) | KR20250017205A (https=) |
| CN (2) | CN116925224A (https=) |
| AU (1) | AU2023247720A1 (https=) |
| CA (1) | CA3246718A1 (https=) |
| CL (1) | CL2024002926A1 (https=) |
| IL (1) | IL315999A (https=) |
| MX (1) | MX2024012216A (https=) |
| WO (1) | WO2023186121A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119930816A (zh) * | 2023-11-02 | 2025-05-06 | 广东菲鹏制药股份有限公司 | 抗cd39人源化抗体或其抗原结合片段及其应用 |
| CN119798442B (zh) * | 2023-12-27 | 2025-12-16 | 华润生物医药有限公司 | 特异性结合cd39的纳米抗体及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108299561B (zh) * | 2018-01-02 | 2020-11-13 | 暨南大学 | 一种pd-1纳米抗体及其克隆表达方法与应用 |
| CA3149494A1 (en) * | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN115551888B (zh) * | 2020-05-12 | 2026-04-28 | 百欧恩泰(珠海)医药研发有限公司 | 抗cd73抗体及其用途 |
| JP2023532234A (ja) * | 2020-06-22 | 2023-07-27 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 抗ｃｄ７３抗体とその用途 |
| WO2022237723A1 (zh) * | 2021-05-12 | 2022-11-17 | 杭州邦顺制药有限公司 | 抗cd39抗体及其制备方法和用途 |
-
2022
- 2022-04-02 CN CN202210345704.7A patent/CN116925224A/zh active Pending
-
2023
- 2023-03-31 CN CN202380031836.5A patent/CN119013298A/zh active Pending
- 2023-03-31 JP JP2025503025A patent/JP2025513930A/ja active Pending
- 2023-03-31 US US18/853,158 patent/US20250230255A1/en active Pending
- 2023-03-31 AU AU2023247720A patent/AU2023247720A1/en active Pending
- 2023-03-31 WO PCT/CN2023/085567 patent/WO2023186121A1/en not_active Ceased
- 2023-03-31 IL IL315999A patent/IL315999A/en unknown
- 2023-03-31 KR KR1020247035805A patent/KR20250017205A/ko active Pending
- 2023-03-31 CA CA3246718A patent/CA3246718A1/en active Pending
- 2023-03-31 EP EP23778485.5A patent/EP4504789A1/en active Pending
-
2024
- 2024-09-30 CL CL2024002926A patent/CL2024002926A1/es unknown
- 2024-10-02 MX MX2024012216A patent/MX2024012216A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113166246B (zh) | 一种抗体及其用途 | |
| CN115551888B (zh) | 抗cd73抗体及其用途 | |
| CN113412281B (zh) | Btn3a结合蛋白及其用途 | |
| JP2021525546A5 (https=) | ||
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| US20240425593A1 (en) | Anti-pd-1 antibody and use thereof | |
| JP7514765B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| US12391770B2 (en) | Compositions and methods comprising antibodies that bind to covalent peptide conjugates | |
| JP2025513930A5 (https=) | ||
| WO2023219147A1 (ja) | Ｃｃｒ８検出用新規抗ｃｃｒ８抗体 | |
| CN119101158A (zh) | 人pd-l2抗体及其使用方法 | |
| CN115505043A (zh) | 特异性结合糖基化ceacam5的抗体 | |
| JP2025512119A5 (https=) | ||
| CN119013305A (zh) | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 | |
| CN109678950B (zh) | spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品 | |
| JP2024542944A5 (https=) | ||
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| JPWO2016171107A1 (ja) | Ｆｇｆｒ２の検出 | |
| JP2024533993A5 (https=) | ||
| KR20190135478A (ko) | 항 gpr20 항체 | |
| JP2024508597A5 (https=) | ||
| JP2025532665A5 (https=) | ||
| HK40048164B (zh) | 一种抗体及其用途 | |
| RU2025116107A (ru) | Антитело и его применение | |
| CN116135885A (zh) | 靶向cd73蛋白的融合蛋白 |